ACADIA reports Phase III Parkinson's Disease Psychosis Trial results - SMTP

http://tinyurl.com/bqmbepx - New behavioral strategies may help patients learn to better control chronic ...

Diagnosing diseases and discovering effective treatments aren't the only challenges facing health care professionals in the United States, said Braden Mogler, the paper's lead author and a third-year medical student at the David Geffen School of ...and more »

High Death Rate from Superbugs and Healthcare Acquired Infections Leads to Heightened Concern

NEW YORK, Nov. 27, 2012 /PRNewswire/ A recent Harris Interactive survey on the attitudes of the American public towards healthcare acquired infections (HAIs) revealed that almost one quarter (24%) of ...

ACADIA reports Phase III Parkinson's Disease Psychosis Trial results

ACADIA reports Phase III Parkinson's Disease Psychosis Trial resultsACADIA Pharmaceuticals Inc. (ACAD: Quote) announced successful top-line results from its pivotal Phase III trial evaluating the efficacy, tolerability and safety of pimavanserin in patients with Parkinson's disease psychosis. Pimavanserin is ACADIA's ...Acadia reports Phase 3 success in Parkinson's drugU-T San DiegoACADIA Pharmaceuticals to Host Conference Call and Webcast on November ...DailyFinanceACADIA Rises Exponentially on Phase III Parkinson's Disease Trial24/7 Wall St.all 36 news articles »